Stockreport

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome [Yahoo! Finance]

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF Mon, February 17, 2025 at 7:02 AM GMT+1 7 min read In This Article IPHA IPHYF Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a fa [Read more]